To outline recent updates in the diagnosis and management of heterozygous familial hypercholesterolaemia.
INTRODUCTION
Familial hypercholesterolaemia comprises a group of inherited genetic defects, characterised by a highly penetrant autosomal dominant pattern of inheritance, which produces a marked increase in LDL cholesterol (LDL-C) concentrations [1] . The vast majority of affected families show only dominant inheritance with heterozygous transmission of the causal gene. Recent developments in genetic technology have made establishing the diagnosis relatively simple, although a clearly defined case finding and cascade testing protocol has not been implemented in many countries worldwide. The purpose of this brief review is to discuss the importance of early recognition of heterozygous familial hypercholesterolaemia (HeFH). Specifically, we will discuss the pros and cons of early identification of HeFH.
Prevalence and natural history of familial hypercholesterolaemia
The prevalence of HeFH in most populations is believed to be between 1/200 and 1/500, and therefore worldwide there are estimated to be 14 and 34 million familial hypercholesterolaemia patients [2] . However, the estimated prevalence of HeFH exceeds currently diagnosed cases worldwide and that is reflected in the screening methodology and the populations tested. The estimated percentage of diagnosed familial hypercholesterolaemia patients ranges from less than 1% in Russia, to 44% in Iceland and 71% in Holland where a targeted screening programme operates [2] .
Long-term follow-up cohort studies exploring the natural history of HeFH have been somewhat limited [2] . A recent report from a familial hypercholesterolaemia registry in Norway [3 && ], examined 4688 genetically confirmed familial hypercholesterolaemia patients between 1992 and 2010. There were 113 deaths and the mean age of death was 61.1 years. Cardiovascular disease was the most common cause of death (46.0%), followed by cancer (30.1%). Compared with the Norwegian population, cardiovascular disease mortality was significantly higher in the registry in all age groups younger than 70 years [standardized mortality ratio 2.29, 95% confidence interval (CI) 1.65-3.19 in men and women combined; standardized mortality ratio 2.00, 95% CI 1.32-3.04 in men; standardized mortality ratio 3.03, 95% CI 1.76-5.21 in women]. The mean age at inclusion in the registry of those who had died was 54.8 years compared with 33.6 years for surviving patients emphasizing the adverse consequences of late diagnosis and treatment for familial hypercholesterolaemia. The mean age for starting lipid-lowering therapy was 33.4 years, with 89% of adults more than18 years on lipid-lowering medication, with a mean LDL-C on treatment of 4.7 mmol/L. This evidence emphasizes the potential cardiovascular consequences of late familial hypercholesterolaemia diagnosis, and suboptimal treatment of LDL-C concentration.
Genetic variants causing familial hypercholesterolaemia
HeFH is mainly caused by either loss of function mutations in LDL receptor (LDL-R) affecting LDL ), there will be an increase in the detection of genetic variants of unknown clinical relevance. It may be possible to clarify whether these variants are pathological using affected family cosegregation studies, but such studies require large numbers of relatives of the affected individual. Other methods include using functional ex-vivo studies to determine the effects of detected gene variants on LDL protein expression levels [9 && ]. The detection of a causative genetic mutation in familial hypercholesterolaemia will depend on whether the patient is deemed to have definite or possible familial hypercholesterolaemia [10], and will be increased in those with higher LDL-C and lower triglycerides pretreatment [11] . In definite familial hypercholesterolaemia the yield for genetic testing for identification of a pathogenic variant approaches 70% and in possible familial hypercholesterolaemia this decreases to 20% [12] [13] [14] . Importantly, how the type of gene mutation affects the response to statin is often uncertain, with considerable overlap between LDL-R and APO-B mutations. In contrast, null LDL-R mutations produce higher LDL-C concentrations and reduced responsiveness to statin treatment [15] . Different LDL-R mutations tend to be associated with higher pretreatment LDL-C levels and differing response to statin treatment [16 & ]. In patients with PCSK9 mutations these tend to have a poor response to statins [17] . Using NGS technology, a recent study has shown that a proportion of mutations in known familial hypercholesterolaemia genes were missed by older mutation detection assays, emphasizing that improvements in technology should help increase mutation detection rates in familial hypercholesterolaemia
A recent study involving patient samples from six different countries has suggested that polymorphisms in particular genes may explain why mutation negative patients have LDL-C levels similar to mutation-positive patients [18 && ]. The variation in those polymorphisms sequenced consistently distinguished familial hypercholesterolaemia mutation negative from healthy individuals. The authors concluded that hypercholesterolaemia
KEY POINTS
Modern registry data suggests an association between late diagnosis and premature cardiovascular death in HeFH patients.
The use of next-generation sequencing (NGS) has increased genetic mutation detection, however, the significance and management of genetic variants of unknown significance remains to be clearly defined.
Targeted screening programmes for HeFH have yet to be implemented in many countries worldwide.
Undertreatment based on LDL-C levels in HeFH is common, however, validated methods of risk stratification beyond LDL-C and family history remain to be fully explored.
The optimum age for commencement of lipid-lowering treatment in children is not known and the proven benefits of treatment-induced decreases in LDL-C concentration in childhood extending into adulthood remain to be confirmed.
in 88% of mutation-negative patients was likely to have a polygenic basis [18 && ]. Interestingly in this study mutation positive HeFH patients with LDL-R and PCK9 mutations were also noted to have a high 6SNP LDL-C gene score that may help explain the variability in penetrance of certain familial hypercholesterolaemia mutations in the relatives of familial hypercholesterolaemia probands. Although these findings need to replicated on a larger scale and cost-benefit analysis will need to be undertaken, use of this score maybe valuable in confirming cases of polygenic hypercholesterolaemia in patients with very high LDL-C who will not benefit from cascade screening.
Diagnostic criteria for familial hypercholesterolaemia in patients and populations
There are a number of validated criteria for diagnosing familial hypercholesterolaemia, which are briefly summarized in Table 1 (for more specific information see relevant references in Table 1 ) and the exact total cholesterol or LDL-C levels vary between each criteria. The best characterized are the Simon Broome Register Diagnostic Criteria [20] for familial hypercholesterolaemia, the Dutch Lipid Clinic Network Diagnostic Criteria for familial hypercholesterolaemia [19] , the US Make Early Diagnosis Prevent Early Death Program Diagnostic Criteria for familial hypercholesterolaemia [21] and the Japanese criteria [22] .
Studies have explored alteration in populationbased total cholesterol cut-offs to increase familial hypercholesterolaemia detections rates. One such study suggested that 88% of the general population in the USA, over the age of 40 years with total cholesterol more than 9.3 mmol/L and LDL more than 6.8 mmol/L and triglycerides less than 2.3 mmol/L were expected to have a familial hypercholesterolaemia causing mutations [21] . This hypothesis has recently been tested in a UK-based population of 4896 public service workers, mean age 44 (þ/À 6) years, of whom 25 (0.5%) were found to have a baseline total cholesterol more than 9.3 mmol/L [23 & ]. This group were then subjected to next-generation sequencing and the detection rate increased to 39% by excluding eight participants with triglycerides over 2.3 mmol/l and reached 75% in those with total cholesterol more than 10.4 mmol/L. The authors conclude by extrapolation that the detection rate of 25% would be achieved with a diagnostic cut-off of 8.6 mmol/L, which would be more clinically useful for familial hypercholesterolaemia in the general population.
Screening for familial hypercholesterolaemia
Familial hypercholesterolaemia fulfils the WHO criteria for screening programmes. Cascade testing from index patients with both clinically defined definite and possible familial hypercholesterolaemia is highly cost-effective when using a combination of DNA testing for the family mutation and LDL cholesterol when it cannot [24] . Over time with the improvements in NGS have reduced the cost of genetic screening, which combined with offpatent medication has resulted in significant cost reductions of up to 50% for potential screening programmes [25 & ]. Universal population screening rather than targeted screening has been shown in the UK population to be the least cost-effective, however, population screening of a sub-group of 16-year olds was potentially as cost-effective, but only if at least 55% of those attended [24] . A recent systematic review concluded that whether familial hypercholesterolaemia screening is cost-effective will depend on the modelling methods used, validity of the screening tests for the relevant population, the price and the efficacy of lipid-lowering therapy [26] .
Current paediatric dyslipidaemia guidelines have recommended checking LDL-C concentration at age 8-10 years and even testing children as young as age 2 years, in those with a relevant family history of familial hypercholesterolaemia [27] [28] [29] . Observational studies in children as young as 8 years, have shown increased carotid intima-media thickness in HeFH compared with normal controls [30 && ]. Barriers to effective cascade testing for identification of familial hypercholesterolaemia have been [20] . (MEDPED, USA) Make Early Diagnosis to Prevent Early Deaths [21] . (Japan) Japanese diagnostic criteria for HeFH [22] .
noted in a recent study on follow-up postcascade screening in the Netherlands [31] . This has shown that less than 30% of patients were seen by a paediatric lipid specialist within 18 months of diagnosis. This clearly has implications not only for advocating early adherence to optimal lifestyle measures for cardiovascular risk reduction but also for starting treatment to decrease LDL-C concentrations. The authors emphasized the need for a coordinated approach such that positive screening results in lipid clinic referral within 6 months to ensure such measures are put in place [31] .
Early recognition of heterozygous familial hypercholesterolaemia management and risk stratification
Current European society guidelines recommends that all patients with familial hypercholesterolaemia and their families undergo intensive education targeting lifestyle management [2] . A consensus has yet to be reached on optimum diet for familial hypercholesterolaemia and a recent meta-analysis has shown that the number of studies were limited and of short duration [32 && ]. The use of plant sterols in familial hypercholesterolaemia reduced mean LDL cholesterol by 0.6 mmol/L and the authors concluded that there is insufficient evidence to support effectiveness of cholesterol-lowering diet [32 && ]. For adults, cholesterol-lowering medications should be initiated immediately at diagnosis. For children, treatment should be strongly considered staring at age 8-10 years in childhood, along with lifestyle management [2]. Current nonfamilial hypercholesterolaemia lipid-lowering therapy guidelines have moved away from LDL targets and moved toward assessing risk and fixed dose statin treatment based on statin potency [33 && ,34]. In a review of RCTs in asymptomatic cardiovascular disease (CVD) evidence of titration to a specific LDL target has not been found as these trials mainly used statins at a fixed dose strategy [34] . Guidance recommends the following LDL targets: less than 3.5 mmol/L in children, less than 2.5 mmol/L in adults and less than 1.8 mmol/L in adults with CVD or diabetes [2] . Statins are first line for both adults and children and at present there are no safety data on the use of statins before age 8-10 years. Currently, there are no randomized controlled trials in HeFH to support these targets, however, they are based on the evidence obtained about the efficacy of statin treatment to lower LDL-C concentration and decrease cardiovascular events in large randomized placebo-controlled trials, in nonfamilial hypercholesterolaemia patients.
A recent meta-analysis of statin treatment in paediatric HeFH has shown that statins effectively lower LDL-C concentrations to levels comparable with adult preventive trials, however, this study has emphasized that the majority of these trials were of short duration, involved surrogate end-points, and did not have long-term safety data [35 && ]. RCT evidence that early treatment in childhood with statins is beneficial is currently not available in terms of reductions in primary cardiovascular outcomes such as death or myocardial infarction and is based on short-term RCTs and extrapolation from nonfamilial hypercholesterolaemia RCT evidence in which primary cardiovascular outcomes are available.
LDL-C burden has also been proposed as concept for supporting early statin introduction in children [2] . This concept has been extrapolated from an observational study studying age-related LDL-C concentrations in a Nordic-based population with HeFH [36] . However, the cumulative LDL-C threshold of 150 mmol/L for development of CVD that was suggested in recent guidelines has not been validated [2] . Furthermore, the threshold used was not explored in the main observational study referenced, so ultimately applying this to individual patient management must be queried. The challenge for clinicians will be balancing clinical benefits of treating children from the age of 10 years with lifelong statin therapy, risk of noncompliance, low event rates and the risk of potential adverse effects such as incident diabetes, myalgia or interference with central nervous system lipid metabolism.
Ezetimibe has been shown to have additional effects in lowering LDL-C concentration when combined with a statin in patients with familial hypercholesterolaemia. However, a randomized control trial studying the combination of ezetimbie with a statin failed to detect a difference in carotid intimamedia thickness, compared with statin alone [37] . At present, there is limited randomized controlled trial (RCT) evidence in HeFH, to guide use of ezetimibe and guidelines have recommended its use as either in combination with a statin or in those patients with statin intolerance. A meta-analysis studying the additional LDL-C reduction attributed to ezetimibe showed a decrease of 18% in LDL-C concentration compared with 16% reduction in nonfamilial hypercholesterolaemia RCTs. [38] . Recent clinical trials have shown some promise in terms of providing new treatment for those who fail to reach optimum targets despite statin or ezetimibe therapy. These trials have been recently reviewed elsewhere [39 LDL-C directly, and the variation may be as much as 25% between direct and indirect measurement of LDL-C [40] . Use of apoB and non-HDL cholesterol has been shown in meta-analysis to be superior in terms of predicting CVD risk and also the statin response and CVD risk [41] . However, use of these markers in HeFH has not yet been fully explored. A recent Spanish-based study found that in a study of nearly 2000 HeFH patients Lp(a) levels more than 50 mg/dl was an independent predictor of CVD risk in men and women [42 & ], however, again these findings will be evaluated in terms of clinical outcomes in planned subsequent studies. Elevated PCSK9 as a consequence of a gain-of-function mutation is a known genetic cause of HeFH, however, elevated plasma levels regardless of mutation type have been shown to influence LDL cholesterol [43 && ], and therefore if the findings of this study are replicated in a larger RCT then measuring PCSK9 levels may become part of work-up as well as a target for treatment in familial hypercholesterolaemia. Recent development in small molecule inhibitors of the LDL-R pathway are of interest and may in the future add to therapeutic regimens for HeFH.
Given that most of the cases detected will be possible familial hypercholesterolaemia, most genetic tests will produce negative results for familial hypercholesterolaemia, with the identification of some genetic variants of uncertain pathological significance. The therapeutic management of these variants and mutation-negative patients remains unclear to date. Although current recommendations indicate that these cases should be labelled as polygenic causes of hypercholesterolaemia, this has implications for screening and the familial hypercholesterolaemia detection rate. That said a low detection rate does not alter the treatment of affected cases [44] . Further studies on the clinical management and long-term studies of the natural history of possible cardiovascular disease with these gene variants, and mutation-negative patients, are urgently required.
CONCLUSION
Familial hypercholesterolaemia is markedly underdiagnosed and undertreated worldwide. The increased availability of NGS screening will mean that the clinician will be faced with previously uncharacterized genetic variants and the optimum method of assessing or managing these remains to be clarified.
Current guidance based on limited evidence, suggests commencement with statin medication from the age of 10 years with lifestyle advice advocated beforehand. Optimum methods for risk stratification for patients with HeFH need to be better refined.
For adults, registry data suggests that the mean age of diagnosis is often very late (e.g. in the fifth decade) giving rise to decades of untreated LDLinducing atheroma burden and even when a diagnosis is established, treatment of LDL-C concentration is often inadequate. 
